vemurafenib

Ligand id: 5893

Name: vemurafenib

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: vemurafenib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 100.3
Molecular weight 489.07
XLogP 5.04
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

References
1. FDA. 
FDA granted approval to vemurafenib for Erdheim-Chester Disease.
Accessed on 08/11/2017. Modified on 08/11/2017. fda.gov, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm583975.htm?utm_campaign=Oncology%2011%2F6&utm_medium=email&utm_source=Eloqua&elqTrackId=7d0bf5ff90bd4c3baeddb8126536c4c0&elq=46dfde430be7466595500f78400ee57f&elqaid=1215&elqat=1&elqCampaignId=712
2. Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y et al.. (2015)
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Cancer Cell28 (3): 384-98. [PMID:26343583]
3. Wang X, Kim J. (2012)
Conformation-specific effects of Raf kinase inhibitors.
J. Med. Chem.55 (17): 7332-41. [PMID:22808911]